Xenetic Biosciences Updates on DNase I Study Collaboration

Xenetic Biosciences, Inc. has revealed that the Bnei Zion Medical Center in Israel has commenced patient dosing in a clinical study. This research investigates the use of systemic DNase I with FOLFIRINOX as a first-line treatment for unresectable pancreatic cancer. Dr. Abed Agbabrya of Bnei Zion Hospital is the principal investigator of this exploratory study. Conducted in collaboration with PeriNess Ltd., the study evaluates the safety, biomarker response, pharmacokinetics, and clinical activity of DNase I. Patient treatment involves DNase I infusions on days 1 and 8 of 14-day cycles.

Xenetic aims to progress its systemic DNase I technology to clinical application. Dr. Dmitry Genkin, Chairman of Xenetic, shared optimism regarding the potential of DNase I to improve responses for patients with challenging conditions. The study analyzes the Objective Response Rate and Progression-Free Survival as part of the clinical activity metric.